Slide 1: Q2 2023 Financial Results & Business Update
Q2 2023 Financial Results & Business Update August 8, 2023 1
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Any statement describing Acumen’s goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and
Slide 3: Agenda
Agenda • Q2 2023 Business Update Dan O’Connell, Chief Executive Officer • ACU193 Clinical Development Update Dr. Eric Siemers, Chief Medical Officer • Q2 2023 Financial Results Matt Zuga, Chief Business Officer & Chief Financial Officer 3
Slide 4: Phase 1 Data Supports Advancing to Phase 2/3
Phase 1 Data Supports Advancing to Phase 2/3 Rapid, dose-related, statistically significant amyloid plaque reduction observed within higher dose cohorts Topline results from INTERCEPT-AD trial demonstrated proof-of-mechanism for ACU193, the first clinical stage AβO- targeting antibody ACU193 was wel
Slide 5: ACU193 Development Summary
ACU193 Development Summary Differentiated profile: Nonclinical and Phase 1 data consistent with toxicity of Ab oligomers and selective binding of ACU193 to Ab oligomers Positive topline results from Phase1 study assessing safety, PK, and target engagement Anticipate next clinical study, follow
Slide 6: Acumen is Well Capitalized, With Expected Cash Runway Into 2H 2026
Acumen is Well Capitalized, With Expected Cash Runway Into 2H 2026 STATUS/ MILESTONES EXPECTED TIMING ~$172M Proof-of-mechanism topline results ✓ Cash, cash equivalents and marketable securities as of June 30, 2023 Biomarker results from Phase 1 study Q4 2023 Anticipated interaction with FDA Q4 2023